RJFSA
APTO

Raymond James Financial Services Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-73
Closed -$195K – 2925
2020
Q1 		$195K Buy
+73
New +$218K ﹤0.01% 2079

Other funds holding APTO

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Raymond James Financial Services Advisors's APTO Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q2 2020, closing a stake of 73 shares — an estimated $195K sold.

Raymond James Financial Services Advisors first reported a position in APTO in Q1 2020 and held it in 1 quarter. The position peaked at $195K in Q1 2020. 58 funds tracked by Wall St. Rank hold APTO as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining Aptose Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 73 Aptose Biosciences, Inc. shares in Q2 2020, an estimated $195K.
  • Raymond James Financial Services Advisors first reported a position in Aptose Biosciences, Inc. in Q1 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Aptose Biosciences, Inc. position peaked at $195K in Q1 2020.
  • 58 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.